Literature DB >> 9146669

Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines.

H Miyake1, K Yoshimura, I Hara, H Eto, S Arakawa, S Kamidono.   

Abstract

PURPOSE: This study was designed to investigate the effect of endogenous basic fibroblast growth factor (FGF-2) on matrix metalloproteinases (MMPs) production and in vitro invasive potential of human bladder cancer cell lines.
MATERIALS AND METHODS: The human bladder cancer cell lines, HT1376 and KoTCC-1, were used in this study. The mRNA for FGF receptor has been shown to be expressed in both cell lines; the mRNA for FGF-2 is expressed in only KoTCC-1. The effects of FGF-2 expression on HT1376 by gene transfection and those of FGF-2 antisense oligonucleotides treatment on KoTCC-1 were analyzed by zymography and in vitro tumor cell invasion assay.
RESULTS: The introduction of human FGF-2 gene into HT1376 cells markedly enhanced both the MMP-2 and MMP-9 production, and the in vitro invasive potential was also increased. In contrast, the exposure of KoTCC-1 cells to FGF-2 specific antisense oligonucleotides decreased the MMP-2 production and in vitro invasive potential, but the exposure to FGF-2 sense oligonucleotides did not.
CONCLUSIONS: These findings suggest that FGF-2 plays an important role in the invasive process of human bladder cancer in part through the regulation of MMPs production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146669

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  Enhanced Sensitivity to NVP-BEZ235 by Inhibition of p62/SQSTM1 in Human Bladder Cancer KoTCC-1 Cells Both In Vitro and In Vivo.

Authors:  Keita Tamura; Kyohei Watanabe; Yuto Matsushita; Hiromitsu Watanabe; Daisuke Motoyama; Toshiki Ito; Takayuki Sugiyama; Atsushi Otsuka; Hideaki Miyake
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.

Authors:  Tibor Szarvas; Frank vom Dorp; Süleyman Ergün; Herbert Rübben
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

3.  Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease.

Authors:  K N Cowan; P L Jones; M Rabinovitch
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

4.  Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3.

Authors:  Thirupandiyur S Udayakumar; Mimi Suzanne Stratton; Raymond B Nagle; George Timothy Bowden
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

Review 5.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.

Authors:  A John; G Tuszynski
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

6.  Keratinocyte growth factor induces matrix metalloproteinase-9 expression and correlates with venous invasion in pancreatic cancer.

Authors:  Kazumitsu Cho; Yoko Matsuda; Junji Ueda; Eiji Uchida; Zenya Naito; Toshiyuki Ishiwata
Journal:  Int J Oncol       Date:  2011-12-06       Impact factor: 5.650

7.  Pathobiology and chemoprevention of bladder cancer.

Authors:  Takuji Tanaka; Katsuhito Miyazawa; Tetsuya Tsukamoto; Toshiya Kuno; Koji Suzuki
Journal:  J Oncol       Date:  2011-09-15       Impact factor: 4.375

8.  Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells.

Authors:  H Miyake; I Hara; K Yamanaka; K Gohji; S Arakawa; S Kamidono
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  An integrative model for recurrence in ovarian cancer.

Authors:  Alexandros Laios; Sharon A O'Toole; Richard Flavin; Cara Martin; Martina Ring; Noreen Gleeson; Tom D'Arcy; Eamonn P J McGuinness; Orla Sheils; Brian L Sheppard; John J O' Leary
Journal:  Mol Cancer       Date:  2008-01-22       Impact factor: 27.401

10.  Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.

Authors:  O Fromigue; N Kheddoumi; J-J Body
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.